Biotechnology & Life Sciences — India ↔ EU Trade Facilitation

Bilateral trade · India ↔ EU

What moves on this corridor.

India exports → EU

USD 4.2B annually — biologics and biosimilars (Biocon, Dr. Reddy's, Intas Biologics); recombinant proteins; monoclonal antibodies (biosimilar bevacizumab, trastuzumab, adalimumab); vaccines (Serum Institute — AstraZeneca Covishield; Pfizer-BioNTech fill-finish; HPV, meningitis); clinical trial services (Fortis Clinical Research, SIRO Clinpharm, Lambda Therapeutic); genomics and diagnostics services

Top India states: Karnataka (Bangalore — Biocon, Kemwell; India's biotech capital), Maharashtra (Pune — Serum Institute; Hyderabad — Dr. Reddy's, Biological E), Telangana (Hyderabad — Biological E, Bharat Biotech, Hetero Biopharma), Gujarat (Ahmedabad — Zydus Lifesciences biologics; Cadila Biologics), Tamil Nadu (Chennai — CRO hub; SciGenom, Equinox Labs)

EU exports → India

EUR 1.8B annually — originator biologics (Roche, Novartis, Sanofi — EU manufactured for India hospital market); EU CRO services (ICON, Syneos, PPD — coordinating India clinical trial sites); EU bioproduction equipment (Sartorius — India operations; Cytiva; Thermo Fisher — bioprocessing); EU diagnostic platforms (Roche Diagnostics, bioMérieux India); specialty chemicals for bioprocessing (Sigma-Aldrich/Merck KGaA)

Top EU buyers: Germany (Bayer — biosimilar licensing; Boehringer Ingelheim — CDMO; Sartorius — bioprocessing equipment; Paul-Ehrlich-Institut — regulatory), Switzerland (Roche — India API and biosimilar; Lonza — CDMO partnership; Novartis — generic/biosimilar), France (Sanofi — India vaccines partnership; EvolentHealth CRO), Sweden (AstraZeneca — Covishield partnership with Serum; Recipharm — CDMO), Ireland (ICON Clinical Research — India CRO sites; Allergy Therapeutics)

Growth rate

+22% CAGR India biotech exports (2019–2024) · Biosimilars +28% CAGR · mRNA vaccine capability +50% CAGR (post-COVID) · India CRO market +18% CAGR

FTA duty impact

Biologics face different tariff treatment from small molecule drugs. Vaccines and biologics (HS 3002): EU MFN typically 0% (WHO Pharma Tariff Elimination). Recombinant proteins (HS 3504): 0% EU MFN. CDMO services (Mode 1): 0% GATS. The primary commercial barrier is EU GMP Biologics (Annex 1/Annex 2 of EU GMP) — not tariffs.

HS codes & tariff rates

Tariff lines that matter.

HS code	Product	EU MFN	FTA rate
`3002.90`	Toxins, cultures, vaccines — biologics	0%	0% (MFN already 0%)
`3504`	Peptones, proteins — recombinant proteins	0%	0% (MFN already 0%)
`3822`	Diagnostic reagents — in-vitro	0%	0% (MFN already 0%)
`Services`	CDMO services — bioproduction (Mode 1)	0% GATS	FTA services chapter
`Services`	CRO services — clinical trials (Mode 1)	0% GATS	FTA services chapter
`2106`	Food preparations — nutraceuticals and functional foods	6%	0% (Year 3)

HS codes and rates are indicative. Verify on EU TARIC before commercial use.

HS code lookup tool →

EU compliance

Required certifications.

EU GMP Biologics (Annex 1 — Manufacture of Sterile Medicines)

New EU GMP Annex 1 (effective August 2023) — the most significant update to EU GMP in 20 years. Applies to all manufacturers of sterile biologics (vaccines, monoclonal antibodies, recombinant proteins) supplying the EU. Key new requirements: Contamination Control Strategy (CCS), enhanced aseptic processing, Rapid Microbial Methods (RMM), environmental monitoring, media fills, container closure integrity. Indian biotech CDMO facilities must have been or be in process of EU GMP Annex 1 re-inspection following the August 2023 update.

EU GMP Annex 1 (2023) · EMA · PIC/S · EUGMP

EMA (European Medicines Agency) Biosimilar Approval

Biosimilars targeting EU market must obtain EMA marketing authorisation via the centralised procedure (mandatory for biologics, including biosimilars). Requires: (1) physicochemical comparability (reference medicine and biosimilar must be analytically indistinguishable); (2) non-clinical studies (in-vitro pharmacology, animal studies if needed); (3) clinical studies (PK/PD equivalence, clinical efficacy and safety — abbreviated vs originator trial). Indian biosimilar companies (Biocon, Dr. Reddy's, Intas) have successfully navigated EMA approval for multiple biosimilars.

EMA centralised procedure · Biosimilar guidelines CHMP/437/04 · EMA Biosimilar FAQ

EU Clinical Trials Regulation (EU 536/2014)

EU Clinical Trials Regulation replaced EU Clinical Trials Directive (2001/20/EC) — streamlined EU clinical trial approval through CTIS (Clinical Trials Information System). For Indian CRO companies managing multinational clinical trials with EU sites: EU-side clinical trial sponsor must submit through CTIS; Indian clinical trial sites in non-EU countries are managed under ICH GCP E6(R2). Indian CRO companies with EU-side sponsor clients must navigate CTIS submission alongside India CDSCO New Drugs and Clinical Trials Rules 2019.

EU CTR 536/2014 · CTIS · ICH GCP E6(R2) · CDSCO NDCT Rules 2019

ICH Q11 (Development and Manufacture of Drug Substances — Biologics)

ICH Q11 (harmonised international guideline for biologic drug substance development and manufacturing) is the foundational reference for all India CDMO facilities producing biologics for EU/US/Japan markets. Indian CDMO facilities must demonstrate ICH Q11 compliance in their regulatory filings and EU GMP inspection readiness. Specifically: process understanding (Design of Experiments approach), comparability protocols, lifecycle management.

ICH Q11 · EMA reflection papers · FDA guidance biologics

EU Regulation 1394/2007 (Advanced Therapy Medicinal Products — ATMPs)

ATMPs include gene therapy, somatic cell therapy, and tissue-engineered products. India's emerging gene therapy and cell therapy companies targeting EU market face ATMP-specific EU GMP, clinical trial, and marketing authorisation requirements. EU ATMP market is growing rapidly (CAR-T, gene therapy) — India biotech companies (Reliance Life Sciences, Stempeutics) have early ATMP development programmes.

EU ATMP Reg 1394/2007 · EMA ATMP CHMP guidelines · CAR-T EU approval pathway

EU compliance checker tool →

Bilateral trade flow

India ↔ EU · the directions.

India → EU (Biotech and Biologics Exports)

Biosimilars — EMA-approved (Biocon: trastuzumab, adalimumab, bevacizumab; Dr. Reddy's: infliximab, filgrastim, pegfilgrastim; Intas Biopharma: etanercept, rituximab); vaccines (Serum Institute — HPV vaccine, meningitis vaccines, COVID-19 vaccines; fill-finish for EU vaccine manufacturers); CDMO services (Kemwell, Biological E — EU pharma/biotech contract manufacturing); CRO services (India clinical trial sites for EU-sponsored multinational trials); genomics and diagnostic services (SciGenom, MedGenome — EU pharma genomic services)

EU → India (Biotech Technology and Products)

Bioprocessing equipment (Sartorius — Germany; Cytiva Sweden — India operations for India biotech manufacturers); originator biologics for India premium hospital market (Roche, Novartis, AstraZeneca); EU CRO services (ICON, PPD, Syneos — managing EU clinical trial sites in multinational India-EU trials); specialty media and reagents for bioproduction (Merck KGaA — Sigma-Aldrich India); gene therapy viral vector technology (European gene therapy CDMOs with India partnerships)

Sector risk framework

Risks · assessment · mitigation.

Risk	Assessment	Mitigation
EU GMP Annex 1 (2023) non-compliance — Indian CDMO facility fails EU GMP inspection post-Annex 1 update	High / Very High	All Indian CDMO facilities with EU GMP certification must be re-assessed against Annex 1 (2023) requirements. EU inspectors will apply new Contamination Control Strategy requirements from all EU GMP inspections post-August 2023. Many Indian facilities have significant gaps — prioritise Annex 1 gap analysis immediately.
EMA biosimilar approval timeline — EU marketing authorisation for biosimilar takes 3–5 years from development start	High / Medium	For biosimilar licensing mandates: structure commission as milestone-based (development milestones + approval milestone + first sales milestone) rather than as a single payment on commercial launch. Biocon, Dr. Reddy's, and Intas already have EU-approved biosimilars — these established companies can deliver faster commercial mandates than new biosimilar developers.
India clinical trial data non-acceptance — EMA scientific committee questions the quality or representativeness of India-conducted clinical data	Low / High	India clinical trial data quality has improved significantly post-CDSCO NDCT Rules 2019. Ensure all India clinical trial sites are NABH-accredited and the CRO is ICH GCP E6(R2) compliant. CTIS requires EU-side sponsor to take responsibility for all data quality regardless of India site management.

3 Ps · viability analysis

Possibility · probability · plausibility.

Possibility

Is this trade structurally viable?

Yes — India's biotech manufacturing base (vaccines 60% global supply, 15+ EMA-approved biosimilars, 800+ biotech companies) is internationally competitive. EU biotech companies with significant development-stage assets and limited manufacturing infrastructure are a natural demand-side partner for India CDMO capacity.

Probability

Will this specific mandate close?

Very High for India CRO mandates (EU pharma sponsors routinely use India clinical trial sites — mandate is primarily about quality CRO introduction and EU sponsor relationship management). High for biosimilar out-licensing mandates (Indian companies with EU-approved biosimilars seeking EU commercialisation partners). Moderate for CDMO mandates (EU biotech seeking India bioproduction — Annex 1 compliance is the bottleneck).

Plausibility

Does the commercial logic hold?

Fully coherent. India CDMO at 40–60% below EU and US bioproduction costs. India clinical trials at 60–70% below US/EU cost. EU biotech companies with Series B/C funding and a biologic asset in Phase 2 are the ideal CDMO mandate counterparty — they need manufacturing capacity; India CDMO has it.

Marketing mix · 10P analysis

The vertical through a 10P lens.

Product

Biologics and biosimilars (monoclonal antibodies, recombinant proteins, vaccines, peptides — EMA-compliant); CDMO services (bioproduction, fill-finish, lyophilisation, aseptic processing — EU GMP Annex 1); CRO services (clinical trial management, Phase I–III, bioavailability/bioequivalence studies); genomics and bioinformatics services; analytical testing (EU-standard batch release testing); ATMP manufacturing (early stage).

Price

India CDMO bioproduction: 40–60% below EU bioproduction for equivalent GMP standard. India clinical trials: EUR 15,000–25,000 per patient enrolled vs EUR 35,000–55,000 in EU (equivalent indication). Commission: 3–6% of CDMO contract value or 3–5% of CRO contract value — reflecting complexity and relationship management investment.

Place

India: Bangalore (Biocon, Kemwell), Hyderabad (Biological E, Bharat Biotech, Hetero Biopharma), Pune (Serum Institute), Ahmedabad (Zydus). EU: Frankfurt (Paul-Ehrlich-Institut — vaccine authority), London (EMA moved to Amsterdam — EMA regulatory), Amsterdam (EMA HQ), Basel (Roche, Novartis — Swiss proximity to EU).

Promotion

Bio-Europe (partnering conference — November, various EU cities), BIO International Convention (US — June; India biotech prominent), DCAT Week New York (March — biotech CDMO/CRO partnering), CPhI Europe Frankfurt (October — pharma and biotech), BioAsia Hyderabad (biennial — India biotech showcase). Association of Biotechnology Led Enterprises (ABLE) — India-side body.

People

Vinod Kumar Jain — India-side CDMO/CRO qualification, Hyderabad/Bangalore biotech network, CDSCO intelligence. Amit Jain — EU biotech company qualification, EMA regulatory intelligence, EU biosimilar approval pathway, EU clinical trial regulation (CTIS).

Process

Three P filter → EU GMP Annex 1 compliance verification (EMA inspection database) → EMA biosimilar approval status (if biosimilar licensing mandate) → CDMO audit capacity assessment → Mandate + NCNDA → EU biotech company (development-stage or commercial-stage) or EU CRO qualification → Introduction → MOU/LOI → Full CDMO agreement → Commission on contract value.

Physical Evidence

EU GMP Certificate (EMA/CDSCO), EMA Marketing Authorisation (if biosimilar licensing mandate), ISO 13485 (for medical device biologics), ICH GCP E6(R2) inspection certificate, NABH accreditation (clinical trial site), commission invoice.

Partners

ABLE (Association of Biotechnology Led Enterprises India), BIRAC (Biotechnology Industry Research Assistance Council), DBT (Dept of Biotechnology India) — India. EuropaBio, EFPIA, EMA, Paul-Ehrlich-Institut — EU.

Performance

Target: 2–4 biotech mandates per year. Commission: EUR 30,000–300,000 per mandate (3–6% on EUR 500K–5M CDMO/CRO contract value). CDMO mandates are the highest-value in this vertical; CRO mandates are shorter cycle.

Purpose

India manufactures the world's vaccines. India develops biosimilars that make life-saving biologics affordable globally. Connecting EU biotech assets with India's manufacturing excellence — and EU clinical expertise with India's patient population — is work of genuine human significance.

Practitioner intelligence

What works · what doesn't.

✓ Success conditions

What works

✓ Targeting development-stage EU biotech companies (Series B/C — have Phase 2 asset, limited manufacturing capacity) for CDMO introductions — these companies need manufacturing capacity, have capital to pay, and have long-term commitment horizons that generate recurring commission income
✓ Verifying EU GMP certificate currency on EMA inspection database before any CDMO introduction — expired or warning-letter EU GMP certificates disqualify an Indian CDMO from EU pharma/biotech clients immediately; this verification step is the most important compliance check in this vertical
✓ Positioning India clinical trials on a cost-per-patient and speed-of-enrolment basis with EU phase 3 sponsors — India's 1.4B population, diverse patient demographics, and 130,000+ clinical trial sites enroll patients faster and cheaper than EU sites for most indications

✗ Failure modes

What doesn't work

✗ Attempting to introduce a non-EU-GMP-Annex-1-compliant Indian CDMO for sterile biologics to EU biotech clients — EU biotech clients cannot use a non-EU-GMP-certified CDMO for their regulatory filings regardless of price; Annex 1 compliance is a binary gate, not a negotiating point
✗ Ignoring EMA EU Clinical Trials Regulation (CTIS) requirements when introducing Indian CROs to EU sponsors — EU-sponsored multinational clinical trials must be submitted through CTIS; Indian CROs without CTIS process knowledge create compliance liability for EU sponsors

Commission structure

How we get paid.

Deal type	Rate	Indicative value
Biologics CDMO — EU biotech Phase 2/3 manufacturing	3–5% contract value	EUR 500K–5M · 18–36 month initial contract · EU GMP Annex 1 mandatory
Biosimilar out-licensing — EMA-approved biosimilar to EU commercialisation partner	2–4% licensing deal value	EUR 2M–20M upfront + royalties · Milestone-based commission structure
CRO — Phase 2/3 clinical trials EU-sponsored in India	3–5% CRO contract value	EUR 300K–3M CRO contract · ICH GCP E6(R2) · CTIS-linked
Vaccine fill-finish CDMO — EU vaccine manufacturer	2–3.5% contract value	EUR 1M–10M · Serum Institute, Biological E, Bharat Biotech
mRNA platform licensing — EU biotech to India	3–5% licensing value	EUR 1M–10M · Post-COVID mRNA technology transfer to India
Genomics and bioinformatics services — EU pharma R&D	3–5% contract value	EUR 200K–1.5M · MedGenome, SciGenom — EU pharma genomic service mandates

Sub-specialisations

Niches we operate in.

Niche

Biosimilar Out-Licensing to EU

Biocon, Dr. Reddy's, Intas — EMA-approved biosimilars seeking EU commercialisation partners. Milestone-based licensing agreements. EU distribution, co-promotion, or full licensing.

2–4% licensing value

Niche

Biologics CDMO for EU Biotech

Kemwell, Biological E, Aragen — EU GMP Annex 1 facilities with bioproduction capacity. EU development-stage biotech seeking affordable GMP manufacturing.

3–5% contract value

Niche

Clinical Trials CRO — India Sites

India is the world's most cost-competitive Phase 2/3 clinical trial location for most major disease indications. EU pharma sponsors reducing US-EU trial costs by including India sites.

3–5% CRO contract

Niche

Vaccine Fill-Finish CDMO

Serum Institute (world's largest vaccine manufacturer) and Biological E offer EU vaccine manufacturer fill-finish capacity at 50–60% below EU CDMO costs.

2–3.5% contract value

Niche

mRNA Technology Platform

Post-COVID: India building mRNA manufacturing capability. EU mRNA platform companies (BioNTech, CureVac technology licensing) seeking India manufacturing partnerships.

3–5% licensing value

Niche

Animal Health Biologics

Indian animal health biologics manufacturers (Hester Biosciences, Indian Immunologicals) — EU animal health companies seeking India-manufactured veterinary vaccines.

3–5% contract value

Active mandates · Biotechnology & Life Sciences

What's open right now.

SELL EU GMP Annex 1 certified biologics CDMO — 4000L bioreactor capacity, mammalian and microbial fermentation, seeking EU biotech Series B/C client for Phase 3 manufacture Bangalore, Karnataka → Germany / Switzerland / Netherlands EU biotech companies

SELL EMA-approved biosimilar portfolio — 5 approved biosimilars (trastuzumab, adalimumab, bevacizumab, etanercept, rituximab), seeking EU commercialisation partner (co-promotion or exclusive licensing) Hyderabad, Telangana → Germany / France / Italy specialty pharma distributors

BUY Swiss biotech company — seeking India CDMO for Phase 2b to Phase 3 transfer of anti-cancer mAb programme, EU GMP Annex 1 mandatory, timeline 12 months to clinical supply Switzerland → India (Bangalore / Hyderabad EU GMP CDMOs)

SELL India CRO — 45 Phase 1–3 trial sites across 8 therapeutic areas, NABH accredited, ICH GCP E6(R2), CTIS-capable support team, seeking EU pharma CRO partnership for multinational trials Mumbai/Bangalore → EU pharmaceutical sponsors (Germany / France / UK)

Mandates anonymised. Introduced under NCNDA. Commission on completion. Submit your mandate →

Context & outlook

How this sector is moving.

Historical context

How this sector evolved

◆ India's biotech industry genesis: Biocon (1978) — founded by Kiran Mazumdar-Shaw — was India's first biotech company. Biocon's first EU biosimilar (insulin glargine) approval in 2020 marked India's arrival as a serious EU biosimilar supplier.
◆ Serum Institute of India's role in COVID-19 vaccine production (2021 — Covishield/AstraZeneca) demonstrated India's capacity for large-scale biologic manufacturing at global scale — producing 2B+ doses of COVID-19 vaccine and establishing India as a strategic biotech manufacturing partner for EU.
◆ India-EU clinical trial relationship has been built over 20+ years — European pharma companies (Pfizer, AstraZeneca, Novartis) have consistently used India clinical trial sites for large Phase 3 multinational trials due to cost, patient diversity, and regulatory data quality.
◆ EMA centralised procedure for biosimilars has been fully used by Indian companies since Dr. Reddy's first EMA biosimilar approval (filgrastim, 2008) — establishing India as the world's second-largest biosimilar supplier to EU after South Korea (Samsung Bioepis).

Future outlook 2025–2030

Where this is heading

▶ mRNA vaccine and therapeutic platforms — India is building mRNA manufacturing capacity (Serum Institute mRNA partnership; BIRAC mRNA grants). EU mRNA platform licensing to India will create a new bilateral biotech technology transfer corridor.
▶ CAR-T and cell therapy — India emerging ATMP sector (RelLife Sciences, Stempeutics). EU ATMP companies (Novartis Kymriah, BioNTech CAR-T) seeking India CDMO partnerships for cost reduction in CAR-T manufacturing.
▶ India biotech PLI scheme (EUR 700M — USD 850M) — PLI for biopharmaceuticals accelerating India biologic manufacturing scale and product range.
▶ AI-driven drug discovery — India AI biotech companies (InvictaBio, Verloop health, Navi-G) partnering with EU biotech for AI-accelerated target discovery and lead optimisation. India computational biology talent at 50–70% below US/EU equivalent costs.

India ↔ EU FTA impact

High impact

Mutual recognition of CDSCO and EMA GMP inspections would eliminate the requirement for Indian CDMO facilities to host separate EMA inspections (which cost EUR 50,000–200,000 per inspection per facility). This directly reduces the cost of EU market entry for Indian CDMO companies and makes India CDMO more price-competitive with EU and US-based CDMOs for EU biotech clients.

Essential documents

From the document library.

Doc 36

EU GMP Guide for Indian Pharmaceutical Exporters

Full EU GMP framework — Annex 1, Annex 2, Annex 3 (biologics-specific sections explained)

→ Doc 87

Clinical Trials Documentation Checklist

ICH GCP E6(R2) document checklist — India clinical trial site documentation standards

→ Doc 65

Pharma & Biotech Sector Factsheet (DOCX)

Full pharma and biotech sector intelligence — distinct from this vertical factsheet

→

Browse all documents →

Applicable FTAs

FTA

India-EU FTA 2026

GMP mutual recognition, clinical trial data acceptance, biosimilar regulatory cooperation — primary FTA benefits for this vertical

Key markets

Country intelligence for this vertical.

Country

Germany

Paul-Ehrlich-Institut (vaccine authority), Bayer biologics, Boehringer Ingelheim CDMO

Country

Switzerland

Roche, Novartis, Lonza CDMO — primary EU/Swiss biotech buyers and technology partners

Country

India

Bangalore (Biocon, Kemwell), Hyderabad (Biological E, Bharat Biotech), Pune (Serum Institute)

All 184 country pages →

Standard operating procedure

SOP-37 · Biotech & Biologics Mandate — EU GMP and EMA Protocol

View SOP

Frequently asked

FAQ · Biotechnology & Life Sciences.

How does India's biosimilar regulatory pathway differ from the EU EMA pathway?

In India: biosimilars are approved by CDSCO under the "Similar Biologics" guidelines (2012, revised 2016) — requiring comparative data (physicochemical, non-clinical, clinical) vs the Indian reference biologic. In the EU: biosimilars are approved by EMA via the centralised procedure under the EU Biosimilar Guidelines — requiring more extensive comparability studies against the EU reference medicine. Key difference: India CDSCO approval does not automatically confer EU EMA approval — Indian biosimilar companies must file separately with EMA, providing EU-market-specific comparability data using the EU reference biologic as comparator. Indian biosimilar companies with EMA approval (Biocon, Dr. Reddy's, Intas, Zydus) have navigated this dual-pathway — companies without EMA approval are limited to India and emerging markets.

What is EU GMP Annex 1 and why did its 2023 revision matter for Indian biologics manufacturers?

EU GMP Annex 1 (August 2023 revised version) is the EU guide on the Manufacture of Sterile Medicinal Products — the regulatory standard all EU-market sterile product manufacturers (including biologics, vaccines, and injectables) must meet. The 2023 revision was the most substantial update in 20+ years — introducing: mandatory Contamination Control Strategy (a formal documented risk-based approach to sterility assurance); enhanced aseptic processing requirements (greater use of Restricted Access Barrier Systems — RABS, and isolators); Rapid Microbial Methods (RMM) validation requirements; mandatory media fill frequency and challenge organism requirements; enhanced environmental monitoring. Indian biologics CDMO facilities with pre-2023 EU GMP certificates must undergo re-inspection against Annex 1 (2023) before they can supply EU clients who require current EU GMP. EU biotech clients should request to see the date of the most recent EU GMP inspection before awarding CDMO contracts.

Travelogue Forum

Have a question or insight on Biotechnology & Life Sciences? Start a thread in Markets & Logistics.

Discuss on the Forum →

Explore Further — Across the AJG Network

🧭

From Scope Scape

Authoritative External Sources

Primary + analyst + press

BioPharma Dive → Biopharma industry news, FDA approvals, clinical readouts, M&A 📡 RSS
World Bank Open Data → Free access to global development data, 2400+ trade indicators via TCdata360 📡 RSS
UN Comtrade → International trade statistics database — detailed merchandise and service trade by partner

🎯

The Guessing Desk

All sources on this topic · filterable

The Guessing Desk — 140 curated sources on "Biotech" → Filter the full catalog of 140 authoritative sources and 109 live RSS feeds by this topic. Export to your RSS reader. Th…

Open The Guessing Desk →

Supplier Nation	EU Share	Trend	India Edge / Context
USA	28.5%	→	R&D dominance
Germany	12.5%	↓	Cost pressure
China	15.5%	→	Biosimilar volume
India ⭐	2.5%	↑	—
South Korea	6.5%	↑	CDMOs

Dimension	EU	UAE	USA	UK	ASEAN	AUS
Mkt Size	85	65	92	78	58	55
Growth	90	82	88	88	80	78
Entry Ease	42	65	32	42	62	65
Reg Safety	38	62	30	38	58	62
Mkt Open	55	55	45	55	58	60
Commission	88	82	90	88	72	75
FTA Boost	85	80	42	65	58	78

All factsheets at a glance

Search 23,577,134 allfrontierglobal.com data points

36 Biotechnology, Life Sciences and Biologics — India ↔ EU

What moves on this corridor.

Tariff lines that matter.

Required certifications.

India ↔ EU · the directions.

Risks · assessment · mitigation.

Possibility · probability · plausibility.

The vertical through a 10P lens.

What works · what doesn't.

What works

What doesn't work

How we get paid.

Niches we operate in.

Biosimilar Out-Licensing to EU

Biologics CDMO for EU Biotech

Clinical Trials CRO — India Sites

Vaccine Fill-Finish CDMO

mRNA Technology Platform

Animal Health Biologics

What's open right now.

How this sector is moving.

How this sector evolved

Where this is heading

High impact

From the document library.

India-EU FTA 2026

Country intelligence for this vertical.

Germany

Switzerland

India

FAQ · Biotechnology & Life Sciences.

Strategic Heat Map

Multilateral Corridor Comparison — Global Overlay

Bilateral vs Multilateral Trade Intelligence

Competitive Intelligence — India vs Competing Nations in the EU Market

Seasonal Trade Calendar

ESG Intelligence & EU Taxonomy Alignment

Supply Chain Resilience Intelligence

RoDTEP Benefit Indicator

India-EU FTA Duty Saving Estimator

Every Direction. Every Configuration. Commission-Only.

📊 Vertical monthly · refreshed monthly

Live Biotechnology & Life Sciences intelligence

📋 Case studies · 2

📍 Cities tagged with Biotechnology & Life Sciences · 2

📄 Long-form essays · 1

Cron-refreshed data — every cadence

Explore the AJG knowledge graph

Biotechnology, Life Sciences and Biologics — India ↔ EU